QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 correction-evolus-q3-adj-eps-011-beats-017-estimate-sales-68967m-beat-67449m-estimate

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36....

 evolus-affirms-fy2025-sales-guidance-of-295000m-305000m-vs-295999m-est

Evolus (NASDAQ:EOLS) affirms FY2025 sales outlook from $295.000 million-$305.000 million to $295.000 million-$305.000 million v...

 evolus-q3-eps-024-beats-026-estimate-sales-68967m-beat-67449m-estimate

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 8.7...

 btig-reiterates-buy-on-evolus-maintains-18-price-target

BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.

 evolus-submits-final-fda-pma-module-for-evolysse-sculpt-injectable-ha-gel

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, to...

 btig-maintains-buy-on-evolus-lowers-price-target-to-18

BTIG analyst Sam Eiber maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $21 to $18.

 needham-downgrades-evolus-to-hold-maintains-price-target-to-22

Needham analyst Serge Belanger downgrades Evolus (NASDAQ:EOLS) from Buy to Hold and maintains the price target from $22 to $22.

 hc-wainwright--co-maintains-buy-on-evolus-lowers-price-target-to-20

HC Wainwright & Co. analyst Douglas Tsao maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $27 ...

 evolus-lowers-fy2025-sales-guidance-from-345000m-355000m-to-295000m-305000m-vs-348308m-est

Evolus (NASDAQ:EOLS) lowers FY2025 sales outlook from $345.000 million-$355.000 million to $295.000 million-$305.000 million vs...

 evolus-q2-adj-eps-023-misses-010-estimate-sales-69387m-miss-82182m-estimate

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.10) by 1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION